Umut Meriç – General Manager, Chiesi Turkey
Two months into the role, Umut Meriç, general manager for Chiesi Turkey, discusses the affiliate’s rapid progression and his plans to ensure Turkish patients benefit from the global company’s latest…
Chiesi, founded in 1935, serves patients in 60 countries, with a total turnover of EUR 1.3 billion per year, in the areas of respiratory disease, neonatal intensive care, allergy, and cardiology. R&D efforts are currently targeting conditions such as cystic fibrosis, organ transplantation, and rare diseases, with approximately 20 percent of annual turnover invested in R&D each year. Chiesi Turkey was founded in 2007, and has grown quickly to become the 50th ranked pharmaceutical company in the market.
Contact Details
Büyükdere Cad. No: 122 Özsezen Business Centre Block C Floor: 3
Esentepe – Sisli 34394 Istanbul / Turkey
Tel: 0212 370 91 00 –
Fax: 0212 370 91 27
info.tr@chiesi.co I
Two months into the role, Umut Meriç, general manager for Chiesi Turkey, discusses the affiliate’s rapid progression and his plans to ensure Turkish patients benefit from the global company’s latest…
Turkey is quickly becoming a regional hub for pharmaceutical industry for management, clinical trials and manufacturing, explains the general manager of Chiesi Turkey. How important is it for the government…
Ismail Yormaz, vice president & regional director south-east at Recordati, shares the management secrets that have helped him grow Recordati into one of the top pharma companies in Turkey. He…
Sule Mene, co-founder, president and CEO of Mene Health Group, shares with PharmaBoardroom the journey of her company starting as the first government-approved CRO of Turkey, its parallel growth alongside…
Tuğçe Koç reveals how Onko Koçsel was able to quickly grow from an in-licenser to a production-oriented pharmaceutical company with an international reach. She also offers her take on how…
Kazim Dinç, chairman of the board of SURDER and former Minister of Health of Turkey, offers his insights into the Turkish OTC and health products market, highlighting the challenges facing…
Despite the sharp decline in the Turkish lira’s value, the general mood among pharmaceutical executives in Turkey is positive. Rather than being discouraged, they are calling upon their resiliency and…
Acibadem’s Mehmet Ali Aydınlar offers his insights into the Turkish healthcare sector, highlighting Turkey’s burgeoning healthcare tourism industry. He also describes Acıbadem’s focus of growth, globalization and fundamental values that…
Murat Kavrar, country manager at Ekol Turkey, offers readers a look at Ekol’s innovative approach to the logistics sector, emphasizing his company’s R&D capacity and eco-friendly solutions that provide client…
With the construction of state-of-the-art public and private hospitals, Turkey is poised to become a global leader in medical tourism. Turkey has always been a popular tourist destination, given…
Abidin Gulmus, founder and chairman of Gen Ilaç, describes the company’s impressive journey to become Turkey’s principle orphan drug distributor and shares his vision for leveraging the company’s domestic expertise…
In 2016 the Turkish Medicine and Medical Devices Agency (TiTCK) implemented a localisation policy to reduce Turkey’s reliance on imports – a few years later, it has created a young,…
Massimo d’Eufemia, head representative of the European Investment Bank (EIB) in Turkey, highlights the importance of Turkey for the EIB and how the country’s geographic position and key economic role…
Tahsin Yüksel, general manager of Teva Turkey, analyzes the strategic importance of pharmaceutical branding in Turkey, shares the story of Teva’s adaptation to the unique market needs, and offers his…
See our Cookie Privacy Policy Here